drugset / Trial / NCT03373786
A Study of RG-012 in Subjects With Alport Syndrome
Non-randomizedSequentialDouble-blindTreatment
Summary
This is a Phase 1, open-label, multi-center study of the safety, pharmacodynamics, and pharmacokinetics of RG-012 administered to subjects with Alport syndrome.
Timeline
- Start
- 2017-12-22
- Primary completion
- 2019-05-20
- Completion
- 2019-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lademirsen | Oligonucleotide (other) | 1.5 mg/kg | Subcutaneous |